PROSPER trial for KRAS G12C mutations

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors (PROSPER)

Phase 1/2 - 403 patients to enroll

Opened in February 2024 at two locations.

Now open in six total US locations

NOTE: All interventional trials involve risk. 

So please consult with your oncology team as well as ask questions of the trial researchers.

NCT06244771 TRIAL LINK:

https://clinicaltrials.gov/study/NCT06244771?term=FMC-376&rank=1&a=2&b=4

AACR24 abstract

FMC-376 a dual inhibitor of ON and OFF states of KRASG12C is broadly active in PDX models of resistance

https://www.abstractsonline.com/pp8/#!/20272/presentation/5638

Link to Post in the KRAS KICKERS Facebook group:

https://www.facebook.com/groups/kraskickers.g12c/posts/963315335565094